Publikationsverzeichnis (Stand 01/12) Prof. Dr. med. Cornelia Gelbmann
A: Originalarbeiten Gelbmann CM, Mül er WE. Specific decrease of high-affinity agonist states of alpha 2-adrenoceptors in the aging mouse brain. J. Neural. Transm. Gen. Sect. 1990;79:131-136. Gelbmann CM, Mül er WE. Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain. Neurobiol. Aging 1992;13: 45-50. Gelbmann CM, Schteingart CD, Thompson SM, Hofmann AF, Barrett KE. Mast cel s and histamine contribute to bile acid-stimulated secretion in the mouse colon. J Clin Invest 1995; 95:2831-2839. Gelbmann CM, Barrett KE. Role of histamine in a rat model of colitis. Inflamm Res 1995; 44: 386-392.
Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca2+-dependent Cl- transport in T84 human colonic epithelial cel s. Am J Physiol 1996;271: C914-C922. Gelbmann CM, Mestermann S, Gross V, Köl inger M, Schölmerich J, Falk W.
Strictures in Crohn's disease are characterized by an accumulation of mast cel s colocalized with laminin but not with fibronectin or vitronectin. Gut 1999;45:210-217.
Lock G, Knöl A, Hauer S, Gelbmann CM, Hel erbrand C, Jilg W, Schölmerich J, Hartmann A. Leberhistologie bei Hepatitis C: Korrelation mit verschiedenen biochemischen und virologischen Parametern. Med Klin 2000, 95:603-607.
Rogler G, Gelbmann CM, Vogl D, Brunner M, Schölmerich J, Falk W, Andus T, Brand K. Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. Scan J Gastroenterol 2001;36:389-398.
Braaden B, Gelbmann CM, Dietrich CF, Caspary WF, Schölmerich J, Lock G.
Qualitative and quantitative clinical evaluation of the laser-assisted ratio analyser of Helicobacter pylori infection by (13)C-urea breath tests. Eur J Gastroenterol Hepatol 2001;13:807-810.
10. Schlottmann K, Gelbmann CM, Grüne S, Lock G, Schölmerich J.
Eine neue Parazentesenadel für Aszites und Pleuraerguss im Vergleich mit der Venenverweilkanüle – Eine prospektive, randomisierte Studie. Med Klin 2001;96:321-324.
11. Gelbmann CM, Rogler G, Gierend M, Gross V, Schölmerich J, Andus T.
Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure to budesonide and disease patterns in Crohn’s disease. Eur J Gastroenterol Hepatol 2001;13:1431-1437.
12. Gelbmann CM, Rogler G, Gierend M, Bregenzer N, Gross V, Andus T und
Schölmerich J. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 2002;97:1438-1445.
13. Leeb SN, Vogl D, Falk W, Schölmerich J, Rogler G, Gelbmann CM.
Regulation of migration of human colonic myofibroblasts. Growth Factors 2002;20:81-91.
14. Bregenzer N, Soldner M, Gelbmann CM, Vogt T, Schölmerich J, Andus T.
Value of abdominal ultrasound screening in patients with benign diseases of the skin. Dtsch Med Wochenschr 2003;128:1699-1702.
15. Rogler G, Gelbmann CM, Leeb SN, Vogl D, Brunner M, Herfarth H, Schölmerich J,
Falk W. Inducible CD40 expression mediates NF-κB activation and cytokine secretion in human
colonic myofibroblasts. Gut 2003;52:1448-1456.
16. Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Schölmerich J, Gelbmann CM,
Rogler G (gleichberechtigte Letztautorschaft). Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 2003;125:1341-1354.
17. Klebl FH, Gelbmann CM, Lammert I, Bogenrieder T, Stolz W, Schölmerich J,
Schlottmann K. Detection of lymph node metastases of malignant melanoma by palpation and ultrasound. Med Klin 2003;98:783-787.
18. Leeb SN, Vogl D, Grossmann J, Falk W, Schölmerich J, Rogler G, Gelbmann CM.
Autocrine fibronectin-induced migration of human colonic fibroblasts.
Am J Gastroenterol 2004;99:335-340.
19. Gelbmann CM, Ratiu NL, Rath HC, Rogler G, Lock* G, Schölmerich J, Kul mann F.
Use of self-expandable plastic stents for the treatment of esophageal perforations and symptomatic anastomotic leaks. Endoscopy 2004;36:695-699.
20. Endlicher E, Gelbmann CM, Knüchel R, Fürst A, Szeimies RM, Gölder S, Schölmerich
Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma and cancer – a pilot study.
Gastrointestinal Endoscopy 2004;60:449-454.
21. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J,
Hel erbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stel ate cel s from different donors. Biochem Biophys Res Commmun 2004;325:191-197.
22. Ratiu N, Rath HC, Büttner R, Gelbmann CM, Klebl F, Kul mann F, Rogler G, Strauch
UG, Schölmerich J, Messmann H. The effect of chromoendoscopy on the diagnostic improvement of gastric ulcers by endoscopists with different levels of experience. Rom J Gastroenterol 2005; 14:239-44.
23. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann
W, Kal inowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-256.
24. Bregenzer N, Schaffler A, Gelbmann CM, Steinkamp M, Reinshagen M, Scholmerich
J, Andus T. Lack of correlation between the vitamin D receptor Fokl start codon polymorphism and bone mineral density in patients with Crohn's disease. Exp Clin Endocrinol Diabetes 2006;114:1-5.
25. Lock G, Dirscherl M, Obermeier F, Gelbmann CM, Hel erbrand C, Knoel A,
Schölmerich J, Jilg W. Hepatitis C - contamination of toothbrushes: myth or reality? J Viral Hepat 2006;13:571-3.
26. Ott C, Ratiu N, Endlicher E, Rath HC, Gelbmann CM, Schölmerich J, Kul mann F.
Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomes. Surg Endosc. 2007;21:889-96.
27. Gelbmann CM, Rümmele P, Wimmer M, Hofstädter F, Göhlmann B, Endlicher E,
Kul mann F, Langgartner J, Schölmerich J. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critical y il patients. Am J Gastroenterol. 2007;102:1221-9.
28. Ratiu N, Gelbmann CM, Rath HR, Herfarth H, Kul mann F, Schölmerich J, Messmann
H. Chromoendoscopy with indigo carmine in flexible sigmoidoscopy screening: does it improve the detection of adenomas in the distal colon and rectum? J Gastrointestin Liver Dis. 2007;16:153-6.
29. Witthöft T, Möl er B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M,
Gelbmann CM, Hüppe D, Niederau C, Alshuth U. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepat. 2007;14:788-96. 30. Factors affecting cecal and ileal intubation time in colonoscopy.
Zuber-Jerger I, Endlicher E, Gelbmann CM. Med Klin (Munich). 2008;103:477-81
31. Zuber-Jerger I, Endlicher E, Kul mann F, Gelbmann CM.
A new grading system to evaluate the risk of endoscopic retrograde cholangio-pancreatography.
32. Endlicher E, Gelbmann CM, Messmann H.
Reflux disease and Barrett’s oesophagus – are there gender specific differences.
33. Zuber-Jerger I, Mül er A, Kul mann F, Gelbmann CM, Endlicher E, Mül er-Ladner U, Fleck
M. Gastrointestinal manifestation of systemic sclerosis--thickening of the upper gastrointestinal wal detected by endoscopic ultrasound is a valid sign.
34. Siebig S, Meinel A, Rogler G, Klebl E, Wrede CE, Gelbmann C, Froh S, Rockmann F,
Bruennler T, Schoelmerich J, Langgartner J.
Decreased cytosolic glucocorticoid receptorlevels in critical y il patients
Anaesth Intensive Care 2010;38:133-40 35. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C,
Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators.
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
36. Kirchner GI, Scherer MN, Obed A, Ruemmele P, Wiest R, Froh M, Loss M, Schlitt HJ,
Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation
Scand J Gastroenterol 2011;46:471-8
37. Lippert E, Klebl FH, Schweller F, Ott C, Gelbmann CM, Schölmerich J, Endlicher E,
Fibrin glue in the endoscopic treatment of fistulae and anastomotic leakages of the gastrointestinal tract
Int J Colorectal Dis. 2011;26:303-11 38. Kirchner GI, Zuber-Jerger I, Endlicher E, Gelbmann C, Ott C, Ruemmele P,
Causes of bolus impaction in the esophagus
Surg Endosc 2011;25):3170-4B: Übersichten
Mül er WE, Stol L, Schubert T, Gelbmann CM.
Central cholinergic functioning and aging. Acta Psychiatr. Scand. Suppl. 1991;366:34-39.
Köl inger M, Gelbmann CM, Holstege A. Leberfibrose: neue Ansätze zur Therapie. Arzneimitteltherapie 1996; 9: 266-271.
Bregenzer N, Lock G, Gelbmann C, Schölmerich J. Diagnostik und Therapie der akuten Oberbauchkolik. Notfall Medizin 1998; 2: 70-77. Gelbmann CM Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease--do we have reliable markers? Inflamm Bowel Dis 2000; 6:123-131.
Messmann H, Endlicher E, Gelbmann CM, Schölmerich J. Fluorescence endoscopy and photodynamic therapy. Digest Liver Dis 2002;34:754-761 Gelbmann CM
Der komplizierte, chronische Verlauf der Hepatitis B, wie lange behandeln?
XXXI. Kongress der Gesel schaft für Gastroenterologie in Bayern, Z Gastroenterol, Beilage Juni 2003 Gelbmann CM Hepatotoxische Nebenwirkungen von Psychopharmaka Neurotransmitter ; Dezember 2006 Gelbmann CM, Jürgen Schölmerich Sekundär sklerosierende Cholangitis bei Intensivpatienten – ein neues Krankheitsbild? Der Gastroenterologe ; Januar 2008
Ruemmele P, Hofstaedter F, Gelbmann CM Nat Rev Gastroenterol Hepato. 2009;5:287-95
Chronical y il children become grown-up. What does the internist learn from the pediatrician?
Internist (Berl). 2010 Apr;51(4):482-8. German.
C: Buchkapitel
Mül er WE, Gelbmann CM, Pilch H. The restoration of age-related receptor deficits, a common mechanism of nootropic activity? In: Pharmacology of Central Ischemia. J. Kriegelstein (ed.) WVG, Stuttgart, 1988, pp. 353-358.
Mül er WE, Gelbmann CM, Cohen SA, Stol L. Age-associated changes of muscarinic cholinergic and N-methyl-D-aspartate receptors in the mouse brain. Partial reconstitution by phosphatidylserine treatment. In: Biology of Aging. C. Balduini and R. Zwilling (eds.) Springer, Heidelberg, 1992, pp: 17-27. Gelbmann CM, Barrett KE. Role of inflammatory cel types. In: Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment. J Schölmerich, W Kruis, H Goebell, W Hohenberger and V Gross, Editors, Kluwer Academic, Lancaster, UK, 1993, pp 62-79. Gelbmann CM, Barrett KE. In vitro models of epithelial pathophysiology. In: Experimental Models of Mucosal Ulceration and Inflammation, TS Gaginella, Editor, CRC Press, 1996, pp 111-131.
D: Fallberichte , Editorials Gelbmann CM, Barrett KE. Editorial: Neuroimmune regulation of human intestinal transport (editorial). Gastroenterology 1993;105: 934-936. Gelbmann CM, Köl inger M, Gmeinwieser J, Leser HG, Holstege A. Schölmerich J. Spontaneous rupture of the liver in a patient with Ehlers Danlos disease type IV. Dig. Dis Sci 1997; 42:1724-1730.
Bregenzer N, Lock G, Gelbmann CM, Schölmerich J.
Schlottmann K, Gelbmann CM, Schölmerich J, Lock G. Die interkostal angelegte perkutane ultraschal gesteuerte Entlastungsgastrostomie (PUG) – Ein Fal bericht. Ultraschall in Med 2000; 21:1-3.
Endlicher E, Gelbmann CM, Schlottmann K, Herfarth H, Rummele P, Friedrich A, Schölmerich J, Kul mann F. Endoskopische Mukosaresektion eines Ösophagusfrühkarzinoms bei Leberzirrhose und Ösophagusvarizen. Z Gastroenterol 2004;42:609-13.
Rieder F, Hamer O, Gelbmann CM, Hel erbrand C, Knol A, Schölmerich J, Lock G. Crohn's disease of the esophagus: treatment of an esophagobronchial fistula with the novel liquid embolic polymer "onyx". Z Gastroenterol 2006;44:599-602.
Schacherer D, Zeitoun M, Buttner R, Gelbmann CM, Obed A, Schlitt HJ, Scholmerich J, Kirchner GI. Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipient. World J Gastroenterol. 2007;13:6090-3.
BAY AREA GYNECOLOGY ONCOLOGY 555 KNOWLES DR ST 203 LOS GATOS CA 95032 PRE-OP REMINDERS FOR YOUR PROCEDURE 1. Read your consent. 2. Please do all of your blood work 2 days before your procedure. Have it drawn at your local hospital lab where procedure will be done. This MAY be able to be done the day of procedure, if you appear 2.5 hours prior to scheduled start time. 3. If you